Proof of concept: used malaria rapid diagnostic tests applied for parallel sequencing for surveillance of molecular markers of anti-malarial resistance in Bissau, Guinea-Bissau during 2014-2017.
Amplicon sequencing
Guinea-Bissau
Molecular markers of antimalarial resistance
Next-generation sequencing
Plasmodium falciparum
Rapid diagnostic tests
pfcrt
pfdhfr
pfdhps
pfk13
pfmdr1
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
26 Jul 2019
26 Jul 2019
Historique:
received:
11
03
2019
accepted:
23
07
2019
entrez:
28
7
2019
pubmed:
28
7
2019
medline:
12
11
2019
Statut:
epublish
Résumé
Large-scale surveillance of molecular markers of anti-malarial drug resistance is an attractive method of resistance monitoring, to complement therapeutic efficacy studies in settings where the latter are logistically challenging. Between 2014 and 2017, this study sampled malaria rapid diagnostic tests (RDTs), used in routine clinical care, from two health centres in Bissau, Guinea-Bissau. In order to obtain epidemiological insights, RDTs were collected together with patient data on age and sex. A subset of positive RDTs from one of the two sites (n = 2184) were tested for Plasmodium DNA content. Those testing positive for Plasmodium DNA by PCR (n = 1390) were used for library preparation, custom designed dual indexing and next generation Miseq targeted sequencing of Plasmodium falciparum genes pfcrt, pfmdr1, pfdhfr, pfdhps and pfk13. The study found a high frequency of the pfmdr1 codon 86N at 88-97%, a significant decrease of the pfcrt wildtype CVMNK haplotype and elevated levels of the pfdhfr/pfdhps quadruple mutant ranging from 33 to 51% between 2014 and 2017. No polymorphisms indicating artemisinin tolerance were discovered. The demographic data indicate a large proportion of young adults (66%, interquartile range 11-28 years) presenting with P. falciparum infections. While a total of 5532 gene fragments were successfully analysed on a single Illumina Miseq flow cell, PCR-positivity from the library preparation varied considerably from 13 to 87% for different amplicons. Furthermore, pre-screening of samples for Plasmodium DNA content proved necessary prior to library preparation. This study serves as a proof of concept for using leftover clinical material (used RDTs) for large-scale molecular surveillance, encompassing the inherent complications regarding to methodology and analysis when doing so. Factors such as RDT storage prior to DNA extraction and parasitaemia of the infection are likely to have an effect on whether or not parasite DNA can be successfully analysed, and are considered part of the reason the data yield is suboptimal. However, given the necessity of molecular surveillance of anti-malarial resistance in settings where poor infrastructure, poor economy, lack of educated staff and even surges of political instability remain major obstacles to performing clinical studies, obtaining the necessary data from used RDTs, despite suboptimal output, becomes a feasible, affordable and hence a justifiable method.
Sections du résumé
BACKGROUND
BACKGROUND
Large-scale surveillance of molecular markers of anti-malarial drug resistance is an attractive method of resistance monitoring, to complement therapeutic efficacy studies in settings where the latter are logistically challenging.
METHODS
METHODS
Between 2014 and 2017, this study sampled malaria rapid diagnostic tests (RDTs), used in routine clinical care, from two health centres in Bissau, Guinea-Bissau. In order to obtain epidemiological insights, RDTs were collected together with patient data on age and sex. A subset of positive RDTs from one of the two sites (n = 2184) were tested for Plasmodium DNA content. Those testing positive for Plasmodium DNA by PCR (n = 1390) were used for library preparation, custom designed dual indexing and next generation Miseq targeted sequencing of Plasmodium falciparum genes pfcrt, pfmdr1, pfdhfr, pfdhps and pfk13.
RESULTS
RESULTS
The study found a high frequency of the pfmdr1 codon 86N at 88-97%, a significant decrease of the pfcrt wildtype CVMNK haplotype and elevated levels of the pfdhfr/pfdhps quadruple mutant ranging from 33 to 51% between 2014 and 2017. No polymorphisms indicating artemisinin tolerance were discovered. The demographic data indicate a large proportion of young adults (66%, interquartile range 11-28 years) presenting with P. falciparum infections. While a total of 5532 gene fragments were successfully analysed on a single Illumina Miseq flow cell, PCR-positivity from the library preparation varied considerably from 13 to 87% for different amplicons. Furthermore, pre-screening of samples for Plasmodium DNA content proved necessary prior to library preparation.
CONCLUSIONS
CONCLUSIONS
This study serves as a proof of concept for using leftover clinical material (used RDTs) for large-scale molecular surveillance, encompassing the inherent complications regarding to methodology and analysis when doing so. Factors such as RDT storage prior to DNA extraction and parasitaemia of the infection are likely to have an effect on whether or not parasite DNA can be successfully analysed, and are considered part of the reason the data yield is suboptimal. However, given the necessity of molecular surveillance of anti-malarial resistance in settings where poor infrastructure, poor economy, lack of educated staff and even surges of political instability remain major obstacles to performing clinical studies, obtaining the necessary data from used RDTs, despite suboptimal output, becomes a feasible, affordable and hence a justifiable method.
Identifiants
pubmed: 31349834
doi: 10.1186/s12936-019-2894-8
pii: 10.1186/s12936-019-2894-8
pmc: PMC6660714
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
252Subventions
Organisme : Maersk Group
ID : OMPC1400002999
Organisme : Else og Mogens Wedell Wedellsborgs Fond
ID : J. Nr 13-15-1
Organisme : Direktør Emil C. Hertz og Hustru Inger Hertz Fond
ID : løbenr. 6.14.2
Organisme : Direktør Emil C. Hertz og Hustru Inger Hertz Fond
ID : løbenr. 13.17.2
Références
Mol Cell. 2000 Oct;6(4):861-71
pubmed: 11090624
Trop Med Int Health. 2004 Jan;9(1):171-7
pubmed: 14728622
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447
pubmed: 15288742
Trop Med Int Health. 2007 Jun;12(6):736-42
pubmed: 17550470
Trop Med Int Health. 2008 Mar;13(3):410-7
pubmed: 18298608
Exp Parasitol. 1991 Oct;73(3):311-6
pubmed: 1915745
J Infect Dis. 2009 Mar 1;199(5):750-7
pubmed: 19210165
PLoS One. 2009 Aug 31;4(8):e6866
pubmed: 19718439
Future Microbiol. 2010 Dec;5(12):1857-73
pubmed: 21155666
Malar J. 2011 Jan 12;10:6
pubmed: 21226910
Antimicrob Agents Chemother. 2012 Jun;56(6):2976-86
pubmed: 22430961
J Infect Dis. 2013 Mar 1;207(5):842-7
pubmed: 23225895
Am J Trop Med Hyg. 2013 Mar;88(3):536-41
pubmed: 23382159
Malar J. 2013 Mar 19;12:106
pubmed: 23510231
J Infect Dis. 2014 Apr 1;209(7):1126-35
pubmed: 24265439
Nature. 2014 Jan 2;505(7481):50-5
pubmed: 24352242
PLoS One. 2014 Feb 04;9(2):e87991
pubmed: 24505344
Mol Biochem Parasitol. 2014 Jul;195(2):107-14
pubmed: 24927641
PLoS One. 2014 Jul 01;9(7):e101167
pubmed: 24984039
Antimicrob Agents Chemother. 2015 Feb;59(2):872-9
pubmed: 25421474
PLoS One. 2015 Apr 22;10(4):e0124671
pubmed: 25902146
Nucleic Acids Res. 2015 Nov 16;43(20):e135
pubmed: 26152304
Malar J. 2015 Sep 29;14:373
pubmed: 26415927
N Engl J Med. 2016 Jun 23;374(25):2453-64
pubmed: 27332904
PLoS One. 2016 Sep 20;11(9):e0161495
pubmed: 27649561
Sci Rep. 2017 Jan 24;7:41108
pubmed: 28117350
Malar J. 2017 Apr 19;16(1):153
pubmed: 28420422
Sci Rep. 2017 May 25;7(1):2398
pubmed: 28546554
Malar J. 2018 Feb 08;17(1):75
pubmed: 29422048
Sci Rep. 2018 Jul 5;8(1):10159
pubmed: 29977002
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9109-13
pubmed: 3057499
Mol Biochem Parasitol. 1993 Apr;58(2):283-92
pubmed: 8479452
Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13944-9
pubmed: 9391132